Toward precision pathology: Deep learning supported fibrosis grading augments performance of international hematopathologists in a large real-world cohort

T Timothy Ebsworth (1Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom) S Sharon Ruane N Neha Bhardwaj (3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom) R Rosalin Cooper (1Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom) A Anna Green D Deborah Hay (3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom) J Jana Ihlow (2Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany) F Fatima Jelloul (7The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Division of Pathology & Laboratory Medicine, Houston, United States) R Rashmi Kanagal-Shamanna P Philip Macklin (3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom) V Vidhya Manohar (3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom) E Edoardo Olmeda (7University of Milan, Milan, Italy) M Mark Ong (4Guy's and St Thomas' NHS Foundation Trust, Department of Cellular Pathology, London, United Kingdom) C Carlo Pescia (7University of Milan, Milan, Italy) A Andres Quesada (1The University of Texas MD Anderson Cancer Center, Houston, United States) S Saad Bashir (2Ground Truth Labs, Oxford, United Kingdom) S Sam Maxwell (2Ground Truth Labs, Oxford, United Kingdom) K Korsuk Sirinukunwattana (2Ground Truth Labs, Oxford, United Kingdom) A Alan Aberdeen (2Ground Truth Labs, Oxford, United Kingdom) J Jens Rittscher (9Institute of Biomedical Engineering and the Nuffield Department of Medicine, Department of Engineering Science, Oxford, United Kingdom) D Daniel Royston (1Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom)

Abstract

Abstract Introduction Evaluation of bone marrow fibrosis is essential in the assessment of newly diagnosed hematological malignancies and important for monitoring disease progression and therapeutic response, particularly in myeloproliferative neoplasms (MPNs). We previously developed an AI-based model, known as Continuous Indexing of Fibrosis (CIF), that can robustly quantitate marrow fibrosis, capturing fibrosis severity and heterogeneity beyond the limits of conventional manual histological assessment. This tool not only supports the diagnosis and classification of MPNs but has also shown significant potential for detecting early disease progression and enhancing the evaluation of novel therapeutics targeting myelofibrosis. In this study we exhaustively evaluate the performance and utility of our research-grade CIF model using a large cohort of clinical bone marrow trephine (BMT) samples from a regional referral centre in the UK. In parallel, we assess its impact on fibrosis grading by a panel of international expert hematopathologists from several leading diagnostic centres.Method CIF ranks predefined tile-level features from reticulin-stained whole slide images (WSIs) of BMTs on a normalized 0-1 scale, with each tile's rank defining its CIF score. The model outputs a range of values, including average sample score and sample heterogeneity. Tile scores were visualized as heatmaps overlaid on reticulin-stained WSIs during validation, enabling highly intuitive model interpretation. To assess performance at scale with real-world clinical data, we analyzed 1000 sequential BMT WSIs (April 2023 - July 2024) from the digital archive of Oxford University Hospitals NHS Foundation Trust. Diagnoses included myeloid (62%), non-myeloid (12%), no evidence of hematological malignancy (20%) and suboptimal samples (7%). A panel of 14 international hematopathologists independently reviewed all WSIs, with 836 (84%) flagged as being of sufficient quality to grade fibrosis. Employing a crossover study design with embedded washout periods, we assessed both intra- and inter-observer variability in fibrosis evaluation, with and without access to the CIF heatmap overlays.Results Although trained on normal/reactive and MPN samples, CIF successfully mapped fibrosis scores in all cases deemed interpretable by our panel, regardless of diagnosis, staining variation or tissue processing quality. Overall intra-rater agreement for WHO myelofibrosis grading among the expert haematopathologists was only 66.3% when reticulin-stained WSIs were re-evaluated without algorithmic support. Inter-rater agreement, assessed with quadratic-weighted Cohen's kappa, ranged from 0.51-0.84 (median 0.65), highlighting the inconsistency in fibrosis grading in real-world practice. These findings challenge historical reports of high concordance when conducted by experienced hematopathologists. CIF heatmap augmentation yielded a small but statistically significant improvement in inter-rater agreement: Cohen's kappa increased to 0.60-0.84 (Wilcoxon signed-rank test, p=0.0017). Consensus on MF grade improved with CIF support (odds ratio 1.43, Wald test, p=0.0001) and crucially, individual pathologist grading aligned more closely with the expert consensus (odds ratio 1.20, Chi-squared test, p=0.0013).Conclusion This study validates the CIF model for quantitative fibrosis assessment using real-world clinical data. CIF performed robustly across a broad range of diagnoses and sample qualities, and heatmap overlays significantly improved inter-observer consensus among expert hematopathologists with minimal prior AI experience. Beyond showcasing our model's utility, these findings expose the limitations of manual fibrosis grading, with important implications for diagnosis, prognostication, treatment eligibility, and the interpretability of clinical trial data. To our knowledge, this represents the largest real-world evaluation of a deep learning-based approach for BMT analysis in hematopathology. These findings lay the foundation for prospective evaluation of CIF model integration into routine diagnostic workflows, with the aim of systematically improving the accuracy and reproducibility of fibrosis grading. This work advances hematopathology towards the standards of objectivity and consistency demanded in the era of precision medicine, with the potential to deliver wide-ranging benefits for patient care and outcomes in MPNs.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 4335-4335
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (21)

T

Timothy Ebsworth

1Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom

S

Sharon Ruane

N

Neha Bhardwaj

3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom

R

Rosalin Cooper

1Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom

A

Anna Green

D

Deborah Hay

3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom

J

Jana Ihlow

2Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

F

Fatima Jelloul

7The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Division of Pathology & Laboratory Medicine, Houston, United States

R

Rashmi Kanagal-Shamanna

P

Philip Macklin

3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom

V

Vidhya Manohar

3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom

E

Edoardo Olmeda

7University of Milan, Milan, Italy

M

Mark Ong

4Guy's and St Thomas' NHS Foundation Trust, Department of Cellular Pathology, London, United Kingdom

C

Carlo Pescia

7University of Milan, Milan, Italy

A

Andres Quesada

1The University of Texas MD Anderson Cancer Center, Houston, United States

S

Saad Bashir

2Ground Truth Labs, Oxford, United Kingdom

S

Sam Maxwell

2Ground Truth Labs, Oxford, United Kingdom

K

Korsuk Sirinukunwattana

2Ground Truth Labs, Oxford, United Kingdom

A

Alan Aberdeen

2Ground Truth Labs, Oxford, United Kingdom

J

Jens Rittscher

9Institute of Biomedical Engineering and the Nuffield Department of Medicine, Department of Engineering Science, Oxford, United Kingdom

D

Daniel Royston

1Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom